Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J. Clin. Neurosci., 17 (2010), 970-974.Francesconi AB, Dupre S, Matos M, Martin
From:New Targeting in the Reversal of Resistant Glioblastomas,2021 Related terms: Neoplasms of the Testis Alan W.PartinMD, PhD, inCampbell-Walsh-Wein Urology, 2021 Primary Chemotherapy With Single-Agent Carboplatin Primary chemotherapy with 1 to 2 cycles of single-agentcarboplatinhas also been inve...
Treatment options at recurrence (rGBM) are even more limited, and clinical trials are typically recommended for these patients5,6. The few recognized treatments, such as lomustine with or without bevacizumab have shown only minimal, if any, effects on overall survival7. Despite hundreds of clini...
Biosimilars to originator bevacizumab (Avastin), such as bevacizumab-bvzr (Zirabev), can deliver substantial savings and/or expanded access to biologic therapy for patients with metastatic colorectal (mCRC) and non-squamous non-small cell lung cancer (mNSCLC). The objective of this study is to ex...
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neuro-Oncol 107(1), 155-164. http://dx.doi.org/10.1007/s11060-011-0722-2.Reardon DA, Desjardins A, Peters KB, et al (2012) Phase II study of carboplatin, irinotecan, and ...
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol. 2012; 107 (1):155–164.Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, et al. Phase II study of carboplatin, irinotecan, and ...
Objective: To assess safety and efficacy of carboplatin in combination with bevacizumab for recurrent high grade glioma.Background Survival of patients with recurrent high grade glioma (HGG) is short. Anti-angiogenic antibody bevacizumab was recently introduced to therapy of recurrent glioblastoma (GBM)...
Field KM, Simes J, Nowak AK, et al (2015) Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol 17:1504-1513Field KM, Simes J, Nowak AK, et al. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol. 2015;17...
The optimal use of bevacizumab (bev) in recurrent glioblastoma (GBM) remains uncertain including the choice between monotherapy or combination therapy as well as the role of continuing bev beyond disease progression. This was a sequential stratified two part randomized phase II s...
Andrew P. MorokoffSpringer USBennett, I.E., Field, K.M., Hovens, C.M., et al., 2017. Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin. J Neurooncol. 131 (2), 321-329....